On Tuesday, Aflac received an upgrade to its Relative Strength (RS) Rating, from 70 to 78.
IBD's unique RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Aflac can continue to show renewed price strength and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Aflac is building a flat base with a 115.50 buy point. See if it can clear the breakout price in volume at least 40% above average.
In terms of revenue and profits, the company has posted three quarters of increasing earnings growth. Revenue growth has not followed the same trajectory, coming in at -40% in the latest report. The company is expected to release its next quarterly numbers on or around Feb. 5.
The company holds the No. 4 rank among its peers in the Insurance-Accident & Healthcare industry group. CNO Financial Group is the No. 1-ranked stock within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
